Published in J Clin Invest on March 01, 2005
Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev (2011) 5.02
Ribosomal S6 kinase 2 is a key regulator in tumor promoter induced cell transformation. Cancer Res (2007) 1.33
Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces osteosarcoma cell invasion. J Biol Chem (2008) 1.29
c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells. Cancer Res (2007) 1.09
A regulatory mechanism for RSK2 NH(2)-terminal kinase activity. Cancer Res (2009) 1.07
Eriodictyol inhibits RSK2-ATF1 signaling and suppresses EGF-induced neoplastic cell transformation. J Biol Chem (2010) 0.97
RSK2 as a key regulator in human skin cancer. Carcinogenesis (2012) 0.96
The p90 ribosomal S6 kinase (RSK) inhibitor BI-D1870 prevents gamma irradiation-induced apoptosis and mediates senescence via RSK- and p53-independent accumulation of p21WAF1/CIP1. Cell Death Dis (2013) 0.89
Understanding the Biology of Bone Sarcoma from Early Initiating Events through Late Events in Metastasis and Disease Progression. Front Oncol (2013) 0.88
Prediction of molecular targets of cancer preventing flavonoid compounds using computational methods. PLoS One (2012) 0.86
Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells. J Cell Mol Med (2008) 0.86
A Rising Cancer Prevention Target of RSK2 in Human Skin Cancer. Front Oncol (2013) 0.85
p90RSK2 is essential for FLT3-ITD- but dispensable for BCR-ABL-induced myeloid leukemia. Blood (2011) 0.83
Primary neoplasms of bones in mice: retrospective study and review of literature. Vet Pathol (2011) 0.83
Functions of Fos phosphorylation in bone homeostasis, cytokine response and tumourigenesis. Oncogene (2010) 0.82
Targeting protein kinases with selective and semipromiscuous covalent inhibitors. Methods Enzymol (2014) 0.77
A Signaling Network Controlling Androgenic Repression of c-Fos Protein in Prostate Adenocarcinoma Cells. J Biol Chem (2016) 0.77
Regulation of osteosarcoma cell lung metastasis by the c-Fos/AP-1 target FGFR1. Oncogene (2015) 0.76
Bacterial Expression, Purification and In Vitro Phosphorylation of Full-Length Ribosomal S6 Kinase 2 (RSK2). PLoS One (2016) 0.75
Kinase inhibitors as potential agents in the treatment of multiple myeloma. Oncotarget (2016) 0.75
The Protein Tyrosine Phosphatase Rptpζ Suppresses Osteosarcoma Development in Trp53-Heterozygous Mice. PLoS One (2015) 0.75
Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res (1987) 24.27
AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer (2003) 8.88
Reaching a genetic and molecular understanding of skeletal development. Dev Cell (2002) 7.55
Molecular interpretation of ERK signal duration by immediate early gene products. Nat Cell Biol (2002) 6.05
c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science (1994) 5.97
Synergistic coupling of histone H3 phosphorylation and acetylation in response to epidermal growth factor stimulation. Mol Cell (2000) 5.79
ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin-Lowry Syndrome. Cell (2004) 5.27
A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet (1995) 4.61
RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature (2002) 4.44
Bone and haematopoietic defects in mice lacking c-fos. Nature (1993) 4.07
AP-1 in mouse development and tumorigenesis. Oncogene (2001) 3.93
Pleiotropic effects of a null mutation in the c-fos proto-oncogene. Cell (1992) 2.78
Cell cycle-dependent variations in c-Jun and JunB phosphorylation: a role in the control of cyclin D1 expression. EMBO J (2000) 2.66
Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol (2002) 2.55
Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: formal histomorphometric and biomechanical analyses. Endocrinology (1999) 2.47
c-fos is required for malignant progression of skin tumors. Cell (1995) 2.39
Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1. Nat Med (2000) 2.36
FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization. Am J Physiol Endocrinol Metab (2003) 2.31
c-Fos transcriptional activity stimulated by H-Ras-activated protein kinase distinct from JNK and ERK. Nature (1994) 2.16
The protein kinase C inhibitors Ro 318220 and GF 109203X are equally potent inhibitors of MAPKAP kinase-1beta (Rsk-2) and p70 S6 kinase. FEBS Lett (1997) 2.03
JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. J Cell Sci (2002) 1.99
Impaired long-term memory and NR2A-type NMDA receptor-dependent synaptic plasticity in mice lacking c-Fos in the CNS. J Neurosci (2003) 1.94
Osteoblasts are target cells for transformation in c-fos transgenic mice. J Cell Biol (1993) 1.70
Pex gene deletions in Gy and Hyp mice provide mouse models for X-linked hypophosphatemia. Hum Mol Genet (1997) 1.69
Rsk-2 activity is necessary for epidermal growth factor-induced phosphorylation of CREB protein and transcription of c-fos gene. Proc Natl Acad Sci U S A (1998) 1.66
Coffin-Lowry syndrome: clinical and molecular features. J Med Genet (2002) 1.60
Phosphorylation of c-Fos at the C-terminus enhances its transforming activity. Oncogene (1996) 1.56
The Mos/MAP kinase pathway stabilizes c-Fos by phosphorylation and augments its transforming activity in NIH 3T3 cells. EMBO J (1995) 1.55
Osteomalacia in hyp mice is associated with abnormal phex expression and with altered bone matrix protein expression and deposition. Endocrinology (2001) 1.43
c-fos expression induces bone tumors in transgenic mice. Oncogene (1989) 1.40
Altered extracellular signal-regulated kinase signaling and glycogen metabolism in skeletal muscle from p90 ribosomal S6 kinase 2 knockout mice. Mol Cell Biol (2001) 1.38
Developmental expression and tissue distribution of Phex protein: effect of the Hyp mutation and relationship to bone markers. J Bone Miner Res (2000) 1.30
Perspectives: signal transduction. Cell survival demands some Rsk. Science (1999) 1.24
c-fos-induced osteosarcoma formation in transgenic mice: cooperativity with c-jun and the role of endogenous c-fos. Cancer Res (1995) 1.24
Activation of the JNK-AP-1 signal transduction pathway is associated with pathogenesis and progression of human osteosarcomas. Bone (2003) 1.14
Ribosomal subunit kinase-2 is required for growth factor-stimulated transcription of the c-Fos gene. Proc Natl Acad Sci U S A (2000) 1.12
Parathyroid hormone induces c-fos promoter activity in osteoblastic cells through phosphorylated cAMP response element (CRE)-binding protein binding to the major CRE. J Biol Chem (1996) 1.08
The structural determinants responsible for c-Fos protein proteasomal degradation differ according to the conditions of expression. Oncogene (2003) 1.04
Identification of a C-terminal tripeptide motif involved in the control of rapid proteasomal degradation of c-Fos proto-oncoprotein during the G(0)-to-S phase transition. Oncogene (2001) 0.93
Proto-oncogene c-fos is transcriptionally regulated by parathyroid hormone (PTH) and PTH-related protein in a cyclic adenosine monophosphate-dependent manner in osteoblastic cells. Endocrinology (1997) 0.90
A PHEX gene mutation is responsible for adult-onset vitamin D-resistant hypophosphatemic osteomalacia: evidence that the disorder is not a distinct entity from X-linked hypophosphatemic rickets. J Clin Endocrinol Metab (1998) 0.84
Effect of age on the expression of Pex (Phex) in the mouse. Calcif Tissue Int (2000) 0.82
Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell (2002) 9.10
AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer (2003) 8.88
Reaching a genetic and molecular understanding of skeletal development. Dev Cell (2002) 7.55
Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Science (2006) 7.35
Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med (2011) 5.66
A validated regulatory network for Th17 cell specification. Cell (2012) 4.82
RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature (2002) 4.44
JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. Cell (2004) 4.28
Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-dependent cell proliferation. Mol Cell (2004) 3.94
Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell (2003) 3.92
The molecular clock mediates leptin-regulated bone formation. Cell (2005) 3.88
Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med (2005) 3.70
The AP-1 transcription factor c-Jun is required for efficient axonal regeneration. Neuron (2004) 3.33
p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet (2007) 3.19
Hormone-sensitive lipase deficiency in mice causes diglyceride accumulation in adipose tissue, muscle, and testis. J Biol Chem (2001) 3.10
Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature (2005) 3.09
Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest (2002) 2.85
Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J Biol Chem (2004) 2.66
c-Jun regulates eyelid closure and skin tumor development through EGFR signaling. Dev Cell (2003) 2.59
Requirement of JNK2 for scavenger receptor A-mediated foam cell formation in atherogenesis. Science (2004) 2.38
Stat5 tetramer formation is associated with leukemogenesis. Cancer Cell (2005) 2.26
Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J Clin Invest (2008) 2.26
Cortical and retinal defects caused by dosage-dependent reductions in VEGF-A paracrine signaling. Dev Biol (2003) 2.24
NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J Biol Chem (2007) 2.22
Genetic analysis of p38 MAP kinases in myogenesis: fundamental role of p38alpha in abrogating myoblast proliferation. EMBO J (2007) 2.21
I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med (2005) 2.21
Impaired postnatal hepatocyte proliferation and liver regeneration in mice lacking c-jun in the liver. EMBO J (2002) 2.15
JunB can substitute for Jun in mouse development and cell proliferation. Nat Genet (2002) 2.07
JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. J Cell Sci (2002) 1.99
Impaired long-term memory and NR2A-type NMDA receptor-dependent synaptic plasticity in mice lacking c-Fos in the CNS. J Neurosci (2003) 1.94
Sustained low efficiency dialysis using a single-pass batch system in acute kidney injury - a randomized interventional trial: the REnal Replacement Therapy Study in Intensive Care Unit PatiEnts. Crit Care (2012) 1.90
Bone mineralization defects and vitamin D deficiency: histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. J Bone Miner Res (2010) 1.88
EGFR signalling as a negative regulator of Notch1 gene transcription and function in proliferating keratinocytes and cancer. Nat Cell Biol (2008) 1.88
c-Jun/AP-1 controls liver regeneration by repressing p53/p21 and p38 MAPK activity. Genes Dev (2006) 1.84
Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin. Nat Cell Biol (2012) 1.81
Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell Metab (2010) 1.79
Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defects. J Cell Biol (2004) 1.77
Control of bone formation by the serpentine receptor Frizzled-9. J Cell Biol (2011) 1.77
The transcriptional profile of mesenchymal stem cell populations in primary osteoporosis is distinct and shows overexpression of osteogenic inhibitors. PLoS One (2012) 1.76
Activation of ERK1/2 by deltaRaf-1:ER* represses Bim expression independently of the JNK or PI3K pathways. Oncogene (2003) 1.76
Promoter specificity and biological activity of tethered AP-1 dimers. Mol Cell Biol (2002) 1.75
Rhabdomyosarcoma development in mice lacking Trp53 and Fos: tumor suppression by the Fos protooncogene. Cancer Cell (2003) 1.71
Increased skeletal VEGF enhances beta-catenin activity and results in excessively ossified bones. EMBO J (2009) 1.68
JNK phosphorylation relieves HDAC3-dependent suppression of the transcriptional activity of c-Jun. EMBO J (2003) 1.67
Directed differentiation of hematopoietic precursors and functional osteoclasts from human ES and iPS cells. Blood (2010) 1.66
Uptake of bone-seekers is solely associated with mineralisation! A study with 99mTc-MDP, 153Sm-EDTMP and 18F-fluoride on osteoblasts. Eur J Nucl Med Mol Imaging (2006) 1.65
Vitamin D deficiency induces early signs of aging in human bone, increasing the risk of fracture. Sci Transl Med (2013) 1.65
Bone morphogenetic protein type IA receptor signaling regulates postnatal osteoblast function and bone remodeling. J Biol Chem (2004) 1.62
TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci U S A (2007) 1.61
Activator Protein 1 transcription factor Fos-related antigen 1 (Fra-1) is dispensable for murine liver fibrosis, but modulates xenobiotic metabolism. Hepatology (2013) 1.59
Modes of implant failure after hip resurfacing: morphological and wear analysis of 267 retrieval specimens. J Bone Joint Surg Am (2008) 1.57
p38alpha: a suppressor of cell proliferation and tumorigenesis. Cell Cycle (2007) 1.57
Sensory neuropathy with bone destruction due to a mutation in the membrane-shaping atlastin GTPase 3. Brain (2014) 1.55
Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease. Arthritis Res Ther (2008) 1.54
Osteoclast size is controlled by Fra-2 through LIF/LIF-receptor signalling and hypoxia. Nature (2008) 1.52
Impaired gastric acidification negatively affects calcium homeostasis and bone mass. Nat Med (2009) 1.52
MKK7 couples stress signalling to G2/M cell-cycle progression and cellular senescence. Nat Cell Biol (2004) 1.51
Targeting inflammation by modulating the Jun/AP-1 pathway. Ann Rheum Dis (2011) 1.51
Estrogen-dependent and C-C chemokine receptor-2-dependent pathways determine osteoclast behavior in osteoporosis. Nat Med (2009) 1.50
Human apolipoprotein E isoforms differentially affect bone mass and turnover in vivo. J Bone Miner Res (2013) 1.47
The Fos-related antigen Fra-1 is an activator of bone matrix formation. EMBO J (2004) 1.46
Jun signalling in the epidermis: From developmental defects to psoriasis and skin tumors. Int J Biochem Cell Biol (2005) 1.45
Metaphyseal fracture healing in a sheep model of low turnover osteoporosis induced by hypothalamic-pituitary disconnection (HPD). J Orthop Res (2013) 1.42
Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients. J Hypertens (2008) 1.42
Mutations in WNT1 cause different forms of bone fragility. Am J Hum Genet (2013) 1.39
Infrared analysis of the mineral and matrix in bones of osteonectin-null mice and their wildtype controls. J Bone Miner Res (2003) 1.39
Micro-structural basis for particular vulnerability of the superolateral neck trabecular bone in the postmenopausal women with hip fractures. Bone (2011) 1.37
The limited role of NH2-terminal c-Jun phosphorylation in neuronal apoptosis: identification of the nuclear pore complex as a potential target of the JNK pathway. J Cell Biol (2005) 1.32
Mouse models for liver cancer. Mol Oncol (2013) 1.31
Differential effects of JNK1 and JNK2 on signal specific induction of apoptosis. Oncogene (2002) 1.30
Canonical Wnt signaling inhibits osteoclastogenesis independent of osteoprotegerin. J Cell Biol (2013) 1.24
Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin gene. J Clin Invest (2002) 1.24
Decrease in the osteocyte lacunar density accompanied by hypermineralized lacunar occlusion reveals failure and delay of remodeling in aged human bone. Aging Cell (2010) 1.24
Mice humanised for the EGF receptor display hypomorphic phenotypes in skin, bone and heart. Development (2003) 1.24
Fos and jun proteins are specifically expressed during differentiation of human keratinocytes. J Invest Dermatol (2005) 1.23
Neuronal survival depends on EGFR signaling in cortical but not midbrain astrocytes. EMBO J (2006) 1.23
Loss of vascular endothelial growth factor a activity in murine epidermal keratinocytes delays wound healing and inhibits tumor formation. Cancer Res (2004) 1.23
JNK2: a negative regulator of cellular proliferation. Cell Cycle (2004) 1.23